Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Apr 05, 2022 1:43pm
128 Views
Post# 34577463

“This is out-of-this-world game-changing.” - Shaf Keshavjee

“This is out-of-this-world game-changing.” - Shaf Keshavjee Over the years ahead UHN will replicate with other organs what has successfully taken place with Lungs.  With the assistance of multiplex diagnostics from SQI, utilization goes from between 1 or 2 in 5, to more than 4 in 5.  This is a significant win for all involved and represents a massive opportunity for SQI.  Don't expect SQI to connect the dots, you will be waiting a long time.  On page 19 of the most recent Investor Presentation a quiet update to the revenue per donor lung was updated to $10K in kit proceeds.  At one time it was suggested it would be closer to $4K.  Clearly the success allowed for premium pricing.  The implications in revenue for participating transplant centers is in the billions of dollars given the million dollar price tag per Lung transplant.  SQI's 1% really adds up $10K at a time, especially as it is rolled out to top global centers that follow Toronto's protocols.

This stock however is controled by few, rather than a wider audience of integrity that scale/diverse volume brings.  There are those that stand to benefit and I get the feeling they tend to escort negative sentiment when ever they can.  The company needs to make a constructive effort to share the story with a wider audience, as clearly not sharing the story allows a few with an agenda to determine value, rather than an informed market of integrity.           

https://www.sshrc-crsh.gc.ca/funding-financement/nfrf-fnfr/stories-histoires/2022/transplantation-eng.aspx


<< Previous
Bullboard Posts
Next >>